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Cotrimoxazole cessation study design
Uganda
Introduction: Cotrimoxazole (CTX) prophylaxis is recommendedby theWorldHealthOrganisation for HIV infect-
ed persons. However, once HIV infected patients have commenced ART in resource limited settings, the beneﬁts
of continued CTX prophylaxis are not known. The few studies that investigated the safety of discontinuing CTX
prophylaxis in these settings had limitations due to their design.
Materials and methods: COSTOP is a randomised double blind placebo controlled non-inferiority trial among HIV
infected Ugandan adults stabilised on anti-retroviral treatment (ART). Participants with CD4 count of 250 or
more cells/mm3 are randomised to two arms: the intervention arm inwhich CTX is discontinued and the control
arm inwhich CTX prophylaxis is continued. The study aims to assesswhether the intervention regimen is not in-
ferior, with respect to the incidence of pre-deﬁned CTX-preventable events, to the control regimen and superior
with respect to the incidence of haematological adverse events.
Discussion: Studies that have previously evaluated the safety of discontinuing CTX prophylaxis amongHIV infect-
ed adults in resource limited settings have providedmoderate to low quality evidence owing in part to method-
ological limitations. COSTOP is designed and conductedwith sufﬁcient rigour to answer this question. The results
of the trial will assist in guiding policy recommendations.
Conclusion: This paper describes the design andmethodological considerations important for the conduct of CTX
cessation studies.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The use of cotrimoxazole (CTX) as prophylaxis against opportunistic
infections among HIV-infected persons is part of the standard of care rec-
ommended by the World Health Organisation (WHO) [1,2]. In resource
limited settings, once HIV infected patients have commenced ART, the
beneﬁts of continued prophylactic CTX medication are not known [1].
A fewstudies in resource limited settings [3–6] have investigated the
effect of providing prophylactic CTX versus no CTX among patients con-
currently takingART. All these studies had limitations in that either they
were observational [3], had small sample sizes [4,5] or followed partic-
ipants for short periods as reviewed by Suthar et al. [6]. This systematic




. This is an open access article undersurvival in HIV infected adults on ART. Further research is needed to de-
termine the optimum duration of CTX treatment in these patients”.
Campbell and colleagues carried out a trial in a home based care setting
in rural Eastern Uganda in which 836 patients who had been on ART for
a median time of 3.7 years and who had a CD4 count above 200 cells/μl
were randomised at household level to continue or discontinue CTX
prophylaxis in an open label design [7]. The trial was stopped at the rec-
ommendation of the DSMB following the occurrence of signiﬁcantly
higher rates of asymptomatic and symptomatic malaria in the group
which stopped CTX (RR = 27.7, 95% CI 6.8, 113.1, p b 0.001). There
was also a signiﬁcantly higher rate of self-reported diarrhoea, but no dif-
ference between the two arms in the incidence of AIDS-related opportu-
nistic infections and no deaths were reported. Recently, a study
conducted in Kisumu—Kenya compared the effect of CTX cessation ver-
sus continuation on a composite outcome of death, malaria, pneumonia
and diarrhoea among HIV infected adults stabilised on ART [8]. None of
these studies used a double-blind placebo controlled design.
A WHO Guideline Development Group on CTX Prophylaxis con-
vened in 2013 recommended the continuation of CTX prophylaxisthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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and high malaria prevalence; but that these guidelines should be
adapted to ‘national context’ [2]. There is still uncertainty within re-
source limited settings and further research is needed to provide evi-
dence based recommendations for or against stopping CTX. Garnering
high quality evidence requires studies with robust designs, methodo-
logical and ethical considerations.
In this paperwe present the design andmethods used in the conduct
of the CTX prophylaxis cessation trial amongHIV infected adults on ART
in Uganda (trial registration number: ISRCTN44723643).
2. Materials and methods
COSTOP is a randomised, double-blind, placebo controlled non-
inferiority trial amongHIV-infected adults in Uganda that have been im-
munologically stabilised on ART. The objective of the study is to assess
whether, in patients with CD4 count of ≥250 cells/mm3, a regime in
which CTX prophylaxis is discontinued is:
(a) not inferior, with respect to the incidence of pre-deﬁned CTX-
preventable events to the control regimen in which prophylaxis
with CTX is continued and
(b) superior to continuing CTX prophylaxis with respect to reducing
the incidence of haematological adverse events.
The pre-deﬁnedCTX-preventable events (Table 1) are a subset of the
WHO-staging events, namely those that are deemed to be CTX-
preventable a priori.
2.1. Study setting and population
The study is being conducted in Uganda at theMRC/UVRI Unit clinics
in Entebbe andMasaka. Patients on long-term CTX and ART care are re-
cruited from local HIV treatment centres situated near-by.
The eligibility criteria used are as follows:
Inclusion criteria
❖ HIV-infected patientwith documented intake of CTX for at least
6 months;
❖ age of ≥18 years;
❖ documented intake of ART for at least 6 months;
❖ clinically asymptomatic;Table 1
Cotrimoxazole preventable WHO staging events.
Cotrimoxazole preventable events
WHO clinical stage 4
Pneumocystis pneumonia
Recurrent severe bacterial pneumonia
Central nervous system toxoplasmosis
Chronic isosporiasis
Recurrent non-typhoidal salmonella bacteraemia
WHO clinical stage 3
Unexplained severe weight loss (N10% of presumed or measured body weight)
Unexplained chronic diarrhoea for longer than one month
Unexplained persistent fever (above 37.6 °C intermittent or constant, for longer
than one month)
Severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or
joint infection, meningitis or bacteraemia)
Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis
Unexplained anaemia (b8 g/dl), neutropaenia (b0.5 × 109 per litre)
or chronic thrombocytopaenia (b50 × 109 per litre)
WHO clinical stage 2
Moderate unexplained weight loss (b10% of presumed or measured body weight)
Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media and
pharyngitis)❖ 2 CD4 counts (not more than 6 months apart) of ≥250 cells/
mm3, the most recent no more than 4 weeks prior to enrol-
ment; and
❖ able to attend study clinics at 3-monthly intervals and in
the event of intercurrent illness.
Exclusion criteria
❖ acute illness (opportunistic infection or other co-morbidity);
❖ ﬁrst trimester pregnancy;
❖ known hypersensitivity to cotrimoxazole; and
❖ grade 3/4 anaemia, neutropenia or thrombocytopenia.
2.2. Ethical approval
Ethical permissionwas obtained from theUganda Virus Research In-
stitute Research and Ethics Committee (UVRI REC), the Uganda National
Council for Science and Technology (UNCST) and the Ugandan National
Drug Regulatory Authority (NDA). The trial ismonitored by an Indepen-
dent Data Monitoring Committee (IDMC).
2.3. Intervention
All participants are required to stop their regular CTX after which
they are randomised to receive CTX tablets of 960mgor amatching pla-
cebo tablet. All participants continue to receive ART from their routine
providers. Trial medication is dispensed monthly for the ﬁrst three
months and three-monthly thereafter with a ﬁxed number of extra tab-
lets to allow for the possibility of late attendance. Participants are re-
quested to return their trial medication packs with any unused tablets
at scheduled clinic visits. Allocated trial treatment is discontinued in
the event of the following: conﬁrmed CD4 count drop to below
250 cells/mm3, participants' consent withdrawal and intercurrent
illness preventing further treatment with trial drug. No additional par-
ticipants are recruited to replace those withdrawn. Participants with-
drawn from trial treatment due to a conﬁrmed CD4 count drop to
below 250 cells/mm3 or due to consent withdrawal are prescribed
open label CTX. Follow-up of participants withdrawn from the study in-
tervention continue unless the participant explicitlywithdraws consent
for follow-up.
2.4. Study schedule
A summary of the study schedule of visits and procedures is shown
in Table 2. Participants are informed about the trial and provide in-
formed consent before screening by signing the informed consent
form. Illiterate participants sign by thumbprint in the presence of an in-
dependent literate witness.
At screening, potential participants are assessed for eligibility, socio-
demographic and behavioural characteristics, and for their medical his-
tory (including ART use and past WHO clinical stage events). A clinical
examination is conducted and Laboratory investigations include a full
blood count, malaria slide and CD4 count.
The enrolment visit takes place within 2 to 4 weeks of screening; el-
igibility is conﬁrmed and consent obtained for randomisation into the
trial. At enrolment and each follow-up visit, routine trial procedures
are performed as indicated in Table 2. Participants are seen monthly
for the ﬁrst three months and 3 monthly thereafter. All participants
are providedwith an insecticide treatedmosquito net (ITN) and educat-
ed about the importance of using it. Other medications and investiga-
tions are provided as required for the management of the participant's
reported disease condition. Participants are encouraged to report to
the study clinics whenever they fall sick. All adverse events (AE) are
Table 2
Summary of study schedule of visits and procedures.
Procedure Assessment time
Screening (weeks−2 to−4) Enrolment (week 0) Week 4 Week 8 Week 12 Week 24 Every 3 months after Every 6 months after
Consent for screening x
Consent for plasma storage x
Consent for enrolment x
History & physical examinationa x x x x x x x
CD4 countb x x x x x
Full blood count x x x x
Pregnancy testc x
Malaria slide x x x x x x
Adherence assessment x x x x x x
Study drug prescription/reﬁll x x x x x x
a Doctor assessment. Including a record of all clinical events and any adverse events since previous visit.
b CD4 counts at baseline, after ﬁrst three months, after 6 months and then 6 monthly thereafter.
c Pregnancy test in all women of reproductive age at screening. Thereafter, only in event of amenorrhea.
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events (SAEs) are reported to the UVRI REC, UNCST and NDA.
2.5. Randomization and blinding
Participants are randomised in a ratio of 1:1 to stop or continue
CTX prophylaxis. The randomisation schedule was produced by an
independent statistician at the MRC/UVRI Unit using random per-
muted blocks of variable size with separate randomisations carried
out in four strata, deﬁned by the four possible combinations
of study site (Entebbe or Masaka) and baseline CD4 count
(250–499 cells/mm3 or ≥500 cells/mm3). Neither study staff nor
the endpoint review committee (ERC) members have access to the
randomisation schedule. Eligible participants details are entered by
the study clinician on the next available row of the enrolment regis-
ter in accordancewith their CD4 count. The trial number correspond-
ing to that row is used on all trial documents and to identify the pre-
labelled study medication.
2.6. Unblinding procedures
The randomisation codes are maintained by the independent trial
statistician and a copy is held by the trial pharmacist. Unblinding is dis-
couraged during treatment; if however, a trial clinician considers it nec-
essary for a participant's allocated treatment to be unblinded this is ﬁrst
discussed with the chief investigator. If unblinding is considered appro-
priate the reason for unblinding is recorded in the unblinding register
and an unblinding form is completed and sent to the independent stat-
istician, or in his absence to the pharmacist. The unblinding information
is disclosed to the attending clinician and is kept conﬁdential to other
study staff and is entered on the database.
2.7. Outcomes
There are two co-primary outcome measures: time to the ﬁrst CTX
preventable event (either one of the WHO staging events in Table 1 or
else a death adjudicated by the ERC to be CTX preventable), and time
to the ﬁrst grade 3 or 4 haematological adverse event. Secondary out-
come measures include the following: all-cause mortality; incidence
of all CTX preventable events, all clinical events and SAEs; incidence,
severity and outcome of all malaria episodes (asymptomatic and symp-
tomatic) conﬁrmed by positive parasitaemia on a blood slide; incidence
of grade 3 or 4 adverse events; mean change in CD4 and haematologic
indices after 12 months; adherence to use of ART, trial drug and ITN.
2.8. Assessment of adherence
Adherence to the use of trial drug, ART and ITN is assessed at every
scheduled and unscheduled visit using a standard adherencequestionnaire and by returned trial drug and ART pill counts. Adherence
counselling is given at every visit. An exit interview questionnaire will
be administered to capture the possible ingestion of CTX either from
supplies left over prior to enrolment or from sources outside the trial
during follow-up.2.9. Sample size
Sample size calculations used the following assumptions: the rate of
CTX preventable events in the control arm would be 10 per 100 PYO,
based on an analysis of event rates from theDART trial [9] among partic-
ipants with conﬁrmed CD4 count above 250 cells/mm3; loss to follow-
up rate would be 4% per year; type I error of 0.05 (one-sided for non-
inferiority), the upper limit of the 95% conﬁdence interval for the hazard
ratio comparing the intervention armwith the control arm should be at
most 1.25 in order to demonstrate non-inferiority; power of 80% assum-
ing equal event rates in the two arms. Under these assumptions a total
of 2000 participants would be required, among whom a total of 494
CTX preventable events would be expected. For the co-primary safety
end-point a sample size of 1000 per arm would have over 80% power
to detect a halving in the rate of grade 3 or 4 haematological events at
the 5% level, assuming that at least 10% of those in the arm that con-
tinues to receive CTX prophylaxis experience such an event. The sample
size was estimated using the formula of Schoenfeld [10].2.10. Trial oversight
The overall trial oversight is provided by the Trial Steering Commit-
tee (TSC). There is an unblinded Independent DataMonitoring Commit-
tee (IDMC) that meets six monthly and is responsible for reviewing
study recruitment targets, the safety and efﬁcacy endpoints and the
available external evidence from other related studies. The IDMC is
also responsible for advising the TSC onwhether to stop, amend or con-
tinue the trial as originally planned. The IDMC can recommend stopping
the trial if there is overwhelming evidence (as determined by the Peto–
Haybittle rule) [11,12] of a difference in the rate of CTX-preventable
events between the two arms.2.11. Ascertainment of the primary endpoints
All potential primary endpoints are captured by the study clinicians
and adjudicated by the ERC. Haematological events (anaemia, neutro-
penia and thrombocytopenia) are assessed through scheduled laborato-
ry tests carried out in the MRC laboratories. Critical CD4 count
measurements (b250 cells/mm3) are conﬁrmed with a repeat test.
The DAIDS toxicity grading tables [13] are utilized to grade the severity
of the measured laboratory parameters.
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Adatabase for the COSTOP trial is customdesigned inMSACCESS. All
CRFs are printed in duplicate and the data is double-entered and vali-
dated before being uploaded into the database. The data from the
Masaka site is transferred and merged with the main trial database in
Entebbe every two weeks. The monitoring of the trial to assess adher-
ence to the protocol, respect of participant rights and data quality is
done routinely by the MRC/UVRI Uganda Research Unit on AIDS moni-
tors and monitors from the East African Consortium for Clinical Re-
search (EACCR) and these are blinded to the treatment allocation.2.13. Analysis plan
Two data sets will be used for analysis namely per protocol (PP) and
intention to treat (ITT) populations. The PP population will consist of all
subjectswhowere considered to have taken at least 80% of their blinded
study medication in each period between scheduled study visits. Study
participants will remain in the per protocol population as long as their
adherence as deﬁned above remains at 80% or higher, and will be
dropped from the PP data set at the visit at which their adherence dur-
ing that period drops to below 80%. Such patients will not re-enter the
PP data set. The ITT data set will consist of all subjects who took at
least one dose of blinded study medication and for whom there is at
least one follow-up assessment.
For the primary analysis of the ﬁrst co-primary endpoint, namely
time to ﬁrst CTX preventable event or death, the analysis will test for
non-inferiority (NI), hence the main analysis will be a per-protocol
(PP) analysis. An ITT analysis will also be done on this population as a
form of sensitivity analysis. For the primary analysis of the second co-
primary endpoint (time to ﬁrst haematological grade 3 or 4 adverse
event) and for all secondary endpoints, analysis will be carried out on
the ITT population.
For all time to event analyses, a subject will be considered to be part
of the trial until the subject experiences the event, or the trial ends, the
subject leaves the trial (due towithdrawal or loss to follow-up), the sub-
ject dies or in the case of the co-primary non-inferiority endpoint, the
subject no longer qualiﬁes for the per protocol population.
The comparative incidence of ﬁrst clinical events in the two study
arms will be illustrated graphically using Kaplan Meier plots. The inci-
dence rate in each arm will be estimated together with 95% conﬁdence
limits, since it is considered safe to stop CTX-prophylaxis if the event
rate in the experimental arm is sufﬁciently low (upper limit of 95%
conﬁdence interval is below 1 per 100 pyar), even if the formal non-
inferiority limit is not met. Non-inferiority will be tested by ﬁtting a
Cox proportional hazards regression model with terms for centre (En-
tebbe or Masaka), CD4 stratum (250–499 cells/mm3 vs. 500 or more
cells/mm3) and treatment arm and calculating the one sided 95% conﬁ-
dence limit for the hazard ratio for the experimental arm (stopping
CTX) relative to the control arm (continuing CTX). The experimental
arm will be deemed to be non-inferior to the control arm if the upper
limit of the conﬁdence interval is less than 1.25, that is, no more than
a 25% increased risk of an endpoint event on the placebo arm. In inves-
tigating whether stopping CTX prophylaxis is superior to continuing
CTX prophylaxis with respect to the safety endpoint of time to the
ﬁrst grade 3 or grade 4 haematological adverse events, an intention-
to-treat approach will be used.
The frequency of such events will be tabulated by treatment arm,
separately for neutropenia, anaemia and thrombocytopenia. Further
analyses will be carried out using survival analysis methods. The inci-
dence of grade 3 or grade 4 haematological adverse events will be illus-
trated graphically usingKaplanMeier plots. The primary analysiswill be
carried out bymeans of a log-rank test, stratiﬁed by the four randomiza-
tion strata deﬁned by the combinations of study site and CD4 stratum, to
compare the event rates between the two study arms. Further analysiswill be carried out by ﬁtting a Cox proportional hazard regression
model, with terms for site, CD4 stratum and treatment arm.
3. Discussion
The aim of COSTOP is to assesswhether CTXprophylaxis can be safe-
ly discontinued among HIV-infected African adults that have achieved
sustained immune reconstitution following initiation of ART in resource
limited settings. According to the recentWHOguidelines [2], completed
studies that have evaluated this concept have providedmoderate to low
quality evidence and the main reason for this is related in part to their
design.
Most clinical trials involving the use of drugs are ‘forward sighted’,
comparing a new drug to a standard, placebo or no treatment at all. In
a situation where stopping the standard treatment (intervention)
needs to be compared to the standard treatment itself (control), the
choice of study design and the methodological considerations to be
made can be quite challenging. A clear example in this case is the design
and conduct of CTX cessation studies.
In our study a non-inferiority designwas required since the goalwas
to determine whether withdrawing CTX would not disadvantage the
participant. The use of a matching placebo in the intervention arm in
which CTX is withdrawn is particularly important to avoid possible
biases associated with knowledge of whether the patient is receiving
prophylaxis. It would be very difﬁcult to maintain cessation of CTX pro-
phylaxis among patients randomised to do so in a setting where CTX is
readily and cheaply available and CTXwidely believed to be always ben-
eﬁcial. Adherence of participants to their allocated treatment arm is
clearly much easier if they are unaware of whether they are receiving
CTX or placebo. If either the investigators or the patients feel that
those allocated to placebo are disadvantaged, this may lead to differen-
tial reporting of events and even prematurewithdrawal of patients from
the trial. This could lead to failure to demonstrate non inferiority when
it actually exists (type II error). Without double blinding, both the pa-
tients and investigatorsmay perceive this to be true based on the previ-
ous evidence that HIV infected patients on ART who stop CTXmay be at
a higher risk of experiencing HIV-related mortality and morbidity [7]
while those continuing on CTXmay be at risk of adverse drug reactions.
The dose of CTX is maintained at 960mg daily as is the current prac-
tice since a reduction could result in increased event rates in the control
arm making it no longer a true control. Study drug and ART adherence
are strictly monitored as differential rates of adherence could lead to er-
roneous conclusions [14]. The primary outcome is a composite of mor-
bidity and mortality due to all CTX preventable WHO staging events.
The criteria developed by WHO for the diagnosis of these events is
based on both deﬁnitive and presumptive evidence by the clinician. In
this study, an Endpoint Review Committee is established to ensure pre-
cise ascertainment of endpoints based on the presumptive/deﬁnitive
WHO criteria [15]. Since some diagnoses based on this criterion involve
some degree of subjectivity, in the absence of the ERC, a high proportion
of incorrect diagnoses could add “noise” to the trial results and hence di-
minish the difference in the arms. All these design considerations are
necessary for the non-inferiority trial to be conducted with rigour and
avoid making false conclusions about the effectiveness of the interven-
tion [16].
We are aware of concerns that patients might have access to unused
supplies of CTX or be able to purchase CTX during the study. Ideally, ad-
herence to trial medicationwould be best assessed by serum level mea-
surements of CTX or its metabolites. However, there is no suitable
method that would only detect serum or urine levels of CTX or its me-
tabolites without being affected by other drugs that patients take. In
the absence of a suitable test it was decided to conduct end-of-trial in-
terviews by independent researchers in order to identify patients who
had possibly taken open label CTX at some time during the trial and
had correctly reported this to the trial team. If participants have such
access, non-inferiority might be inappropriately demonstrated.
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the COSTOP trial highlighting some important aspects in designing
CTX cessation studies. It is expected that the design andmethodological
considerations will signiﬁcantly contribute to the quality of evidence
from this study.
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